AC Immune welcomes Dr. Alan Colowick to its Board of Directors

– SWITZERLAND, Lausanne –  AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Dr. Alan Colowick, MD, MPH, a deeply experienced biotech and investment executive, to its Board of Directors effective immediately.

“The wealth of experience and credibility Dr. Colowick brings to AC Immune’s Board will be invaluable as we continue to execute on our corporate strategy and reinforce our scientific leadership in the field of neurodegenerative diseases. His extensive expertise in biotech from both industry and investment standpoints – including from Celgene, Amgen and Sofinnova – will bring an important perspective to our pipeline and corporate development. We are thrilled to welcome him as our newest Director.” said Board Chairman, Dr. Douglas Williams.

About Dr. Alan Colowick

Dr. Colowick has more than 20 years of industry experience in both large and emerging biotech companies, serving in a broad array of board, senior executive, clinical, regulatory, and commercial positions. He has a deep understanding of value creation and growth strategies, serving as a Partner at Sofinnova Investments, where he led investments for several clinical-stage companies.

Before his time at Sofinnova, Dr. Colowick was EVP and served in various leadership roles at Celgene Corporation, including as President for Celgene’s Europe, Mid-East, and Africa regions and as SVP, Global Medical Affairs.

Before joining Celgene, he was the CEO at Gloucester Pharmaceuticals, Inc. where he led a private round of financing before the acquisition by Celgene in 2010. Dr. Colowick has also served as the President of Oncology at Geron Corporation, as CMO of Threshold Pharmaceuticals, and in numerous positions of increasing responsibility at Amgen culminating with his role as VP, Medical Affairs Europe.

Dr. Colowick also has extensive Board experience that includes current roles on the Board of Directors for Personalis, Inc., XyloCor Therapeutics, and InCarda Therapeutics, and prior roles as Chairman of the Board including VelosBio (sold to Merck in 2020 for $2.75 billion) and Principia Biopharma (sold to Sanofi in 2020 for $3.7 billion).

Dr. Colowick said: “I am delighted to be elected to the Board of Directors at what is a particularly exciting moment for AC Immune. By pioneering a personalized medicine approach that properly recognizes the complexity of the neurodegenerative disease, the Company has positioned itself at the forefront of the field, poised for sustained growth. I look forward to working with my new colleagues as we continue to advance one of the industry’s broadest and most diversified pipelines in neurodegeneration.”

He received his medical degree from Stanford University, a Master’s in Public Health from Harvard University, and a B.S. in Molecular Biology from the University of Colorado. Additionally, Dr. Colowick has completed specialty training in Hematology-Oncology at Harvard Medical School, the Dana Farber Cancer Institute, and Brigham and Women’s Hospital in Boston, USA.

About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team